Vitruvias Therapeutics thyroid tablet recall: FDA issues serious Class I warning over ‘superpotent’ medici
- Posted on September 24, 2026
- By Business News Today
- 1 Views
- 1 min read
In brief
The FDA has issued a critical Class I safety alert regarding Vitruvias Therapeutics thyroid medication following detection of excessive hormone concentration in specific batches. Patients using Thyroid Tablets USP 30mg from Lot 504950 face potential health risks due to higher-than-intended potency levels. This recall emphasizes the importance of immediate medical consultation for affected individuals to prevent adverse complications related to thyroid hormone overdose.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
Vitruvias Therapeutics thyroid tablet recall: FDA issues serious Class I warning over ‘superpotent’ medici
Vitruvias Therapeutics thyroid tablet recall: The FDA has issued a serious Class I recall for one lot of Vitruvias Therapeutics thyroid tablets after the medicine was found to be potentially “superpotent.” The recalled Thyroid Tablets, USP 30 mg may contain more thyroid hormone than intended, raising concerns about serious health effects. Patients currently taking Thyroid, USP from Lot 504950 should contact their healthcare provider.
